Cantor Fitzgerald analyst Caroline Corner reiterated a Buy rating and boosted her price target on Aerie Pharma (NASDAQ: AERI) to $40.00 (from $30.00) after the company announced positive results from the Rhopressa Phase III Rocket 2 trial.

Corner commented, "We are pleased to see this development and, as we expected, the company said it will file for a New Drug Application (NDA) in mid-2016, which we think puts the company on track for product launch, if approved, in mid-2017."

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $18.00 yesterday.

Analyst Comments Analyst PT Change

Canaccord Genuity Raised Price target on Aerie Pharma (AERI) Following Rocket 2 Data September 17, 2015 10:09 AM RBC Capital Boosts PT on Aeri Pharma (AERI) to $44 Following Rhopressa Phase 3 DataSeptember 17, 2015 9:00 AM Aerie Pharma (AERI) PT Raised to $48 at Brean CapitalSeptember 17, 2015 6:59 AM Aerie Pharma (AERI) PT Raised to $45 at Needham & CompanySeptember 17, 2015 6:22 AM Aerie Pharma (AERI) Announces Rhopressa Phase 3 Met Primary Efficacy EndpointSeptember 16, 2015 4:04 PM Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy ResultsSeptember 16, 2015 4:01 PM